Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and
Benzinga Pro data, Bionano Genomics (NASDAQ:BNGO) reported Q4 sales of $6.30 million. Earnings fell to a loss of $22.95 million, resulting in a 10.58% decrease from last quarter.
Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $6.30 million which beat the analyst consensus estimate of $5.57 million by 13.11 percent. This is a 57.89 percent increase over sales of $3.99 million the same
Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.